PROJECT SUMMARY/ABSTRACT
The US is in the midst of an opioid abuse and overdose epidemic. Oxycodone is one of the most prescribed
analgesics, is the first opioid many people experience, and has physiochemical properties that allow it to
accumulate in the brain at rates higher than other opioids, perhaps explaining its considerable abuse potential.
Here, I seek to perform high-throughput experiments to generate brain-wide data on the cellular and molecular
mechanisms of cue-induced reinstatement to oxycodone seeking. Specifically, I propose to use FosCreER mice
to fluorescently `tag' neuronal ensembles activated by cue-induced reinstatement. I will then use cutting-edge
transcriptomics to identify relapse-related genes in these cellular ensembles that drive reinstatement. I will then
prioritize, and test, whether these genes may serve substrates for the development of novel medications to
prevent relapse using a ”circuit therapeutic” approach. In aim 1, iDISCO+, a lipid clearing method, will produce
brain-wide data on regions activated by relapse. I will then use ClearMap, a published Python package, to
conduct high-throughput detection of activated neurons and registration of coordinates onto the Allen Brain
Atlas. I will then rigorously examine this large data set, and test whether reinstatement-responsive cell
ensembles in prioritized structures contribute to relapse behavior. In aim 2, I will focus on cellular populations
in brain regions shown to be required for relapse-related behavior, and will again tag neurons activated by
reinstatement in these sites. Tissue will be dissected, and fluorescence activated cell sorting will be used to
isolate these activated neurons for trancriptomic profiling via RNA-Seq. Together, these two aims will yield
large data sets directly related to the neurocircuitry and molecular biology of reinstatement of oxycodone
seeking. I will once again rigorously analyze these data sets, with strict adherence to pre-established criteria,
to prioritize reinstatement-responsive genes most likely to represent efficacious targets for development of
novel pharmacotherapeutics. Following completion of the training phase, in aim 3 I will extend these findings to
both rat and mouse models of self-administration, and will validate that these transcriptomic adaptations occur
across species, and that they are detected as changes in functional proteins. Once again, I will rigorously
prioritize these targets for translational potential. In aim 4 I will use pharmacological agents that modulate
prioritized protein targets to determine whether they can block cue-induced reinstatement of oxycodone
seeking, focusing on compounds that may be able to quickly move into clinical settings. The training added in
this proposal will allow me to emerge as an exceptionally well-rounded independent investigator. During my
independent career I will perform translational research to develop novel circuit-based therapeutics for
prevention of relapse.